The increase was primarily attributable to $37.3 million in net proceeds received from the issuance of shares of our Series D convertible preferred stock in February 2019, offset by cash used in …

More HOOKIPA Pharma Reports First Quarter 2019 Financial Results and Recent Business Highlights Videos